Location
Mettawa
Posted
June 20, 2026
Commute
Local Area
Local Opportunity Near You!
This job is in your area. Enjoy a short commute and work close to home.
Job Description
Company Description
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, (https://www.linkedin.com/company/abbvie/) Facebook, Instagram (https://www.instagram.com/abbvie/) , X (https://twitter.com/abbvie) and YouTube. (https://www.youtube.com/user/AbbVie)
Job Description
AbbVie is looking for a Director of Oncology US Market Access Marketing, ETENTA. This position is responsible for market access marketing leadership for ETENTA (etentamig), a bispecific antibody in development for Multiple Myeloma. ETENTA is in late-stage cl...
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, (https://www.linkedin.com/company/abbvie/) Facebook, Instagram (https://www.instagram.com/abbvie/) , X (https://twitter.com/abbvie) and YouTube. (https://www.youtube.com/user/AbbVie)
Job Description
AbbVie is looking for a Director of Oncology US Market Access Marketing, ETENTA. This position is responsible for market access marketing leadership for ETENTA (etentamig), a bispecific antibody in development for Multiple Myeloma. ETENTA is in late-stage cl...